The patients were part of the part B study that enrolled about 47 out of 120 patients with renal cell carcinoma, bladder cancer, non-small cell lung cancer, and head and neck squamous cell carcinoma. Four out of the first 16 patients evaluated met the primary endpoint by achieving the clinical benefit of a stable disease condition for six months. Investors were pleased to learn that the study had enrolled 20 patients with renal cell carcinoma. The study aimed to have at least three patients of 30 in each group show clinical benefit in the form of complete or partial response or a stable disease condition for at least six months. The study was conducted on patients with different types of solid tumours before the renal cell carcinoma (RCC) group achieved its primary endpoint ahead of schedule while still enrolling patients.Ĥd Pharma’s study was focused on patients with metastatic tumours who had been heavily pre-treated with a prior immune checkpoint inhibitor (ICI) and shown clinical benefit before the disease progressed later. Also read: Best Healthcare Stocks to Buy Right Now.

4d pharma share price